Objectives To assess the ef®cacy and safety of trospium chloride (TCl, 20 mg twice daily) in the treatment of detrusor instability, compared with placebo. Patients and methods In all, 208 patients were allocated at random to either TCl or placebo in a double-blind clinical study; the patients were treated for 3 weeks. Urodynamic values were measured at the beginning and end of the treatment period. Adverse events were recorded on patient diary cards. A con®rmatory adaptive procedure with one planned interim analysis was used to evaluate ef®cacy. Results Trospium chloride produced signi®cant improvements in maximum cystometric bladder capacity (median treatment effect 22.0 mL, mean 37.3 mL, one-sided P=0.0054) and urinary volume at ®rst unstable contraction (median treatment effect 45.0 mL, mean 63.6 mL, one-sided P=0.0015). The patients' assessment of ef®cacy showed signi®cantly greater clinical improvement in the TCl group than in the placebo group (two-sided P=0.0047). Furthermore, TCl was well tolerated, with similar frequencies of adverse events reported in both groups (68% in the TCl and 62% in the placebo group). Conclusion Trospium chloride (20 mg twice daily) is an effective and safe option for the treatment of detrusor instability.
Introduction
The ICS de®nes detrusor instability as an unstable bladder shown objectively to contract spontaneously or on provocation during the ®lling phase while the patient is attempting to inhibit micturition [1] . Hyperactivity of the bladder, resulting in increased frequency of micturition, nocturia and urgency or even urge incontinence, may considerably compromise the patient's quality of life [2] .
The cause of pathological bladder conditions may be disorders of the neural structures controlling micturition or an unphysiologically high input of afferent impulses from the periphery [2, 3] . The mainstay of the pharmacological treatment of urge incontinence is to in¯uence the nervous supply to the bladder by blocking acetylcholine at the muscarinic receptor site, thus inhibiting bladder contractility and stabilizing the detrusor muscle [4, 5] .
Trospium chloride (TCl; azonia-3-a-benziloyloxy- Because TCl is less lipid-soluble than tertiary ammonium derivatives like oxybutynin, it does not cross the blood±brain barrier to the same extent. An open Phase I study comparing the effects of TCl and oxybutynin on quantitative electroencephalography (EEG) in healthy volunteers showed a signi®cant decrease of a-and b-1 activity after oxybutynin but not after intravenous or oral TCl [9] .
The objective of the present trial, using an adaptive design, was to determine the ef®cacy and safety of TCl vs placebo in the treatment of detrusor instability in patients with urinary urgency and frequency.
Patients and methods
The study was a placebo-controlled, double-blind, multicentre Phase III clinical trial with two parallel treatments, performed in 13 centres in the UK and three in Poland. From 1995 to 1997, 208 patients with symptoms of detrusor instability con®rmed by urodynamic diagnosis were allocated at random to receive either TCl 20 mg twice daily or placebo for 21±24 days after a washout period of 7 days. Upon inclusion in the study, each patient was assigned in chronological order to one of the randomization numbers using a computergenerated randomization list.
According to the trial protocol, patients with con®rmed detrusor instability had to be aged 18±70 years, with normal body weight, vital signs, and age-appropriate ECG ®ndings. The main exclusion criteria were stress incontinence con®rmed by medical history, closed-angle glaucoma, tachydysrhythmias, mechanical stenoses of the gastrointestinal tract or urinary outlet obstruction, myasthenia gravis, allergies, and other severe diseases. Concomitant treatment with other anticholinergics, antidepressants, a-blockers and b-sympathomimetics was not allowed. The study was performed in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki. The study was conducted by a contract research organization to exclude the possibility of a sponsor bias. Before the start of the study, appropriate ethics committee approvals were obtained from each participating centre. Before enrolment, written informed consent was obtained from each patient.
The medical history of each patient was recorded 7 days before initiating study medication. The inclusion and exclusion criteria were checked 7 days before the start of the study and again on the ®rst day of treatment. Urodynamic measurements, a physical examination, recording of vital signs, clinical laboratory tests and ECG recordings were conducted 7 days before initiating the study medication and at the end of the study. In accordance with the ICS Guidelines, urodynamic variables were measured by cystometry (with the patient seated) using saline (room temperature) at a ®lling rate of 60 mL/min. An independent centre reviewed all cystometric records to con®rm detrusor instability. The patients recorded the coated tablets taken, and any adverse events, on a diary card. Overall assessments of safety and ef®cacy by the patient and investigator were carried out at the end of the study.
Ef®cacy and safety variables
The two primary ef®cacy variables were maximum cystometric bladder capacity and the volume at ®rst unstable contraction. Secondary ef®cacy variables included the volume reached at maximum contraction, maximum detrusor pressure at ®rst unstable contraction, bladder compliance, residual urine volume, detrusor pressure at maximum¯ow, and an assessment of ef®cacy by the investigator and the patient using a four-point score (marked improvement, slight improvement, no improvement, worsening).
Safety was evaluated based on adverse events, physical examinations, vital signs, ECGs, and the clinical laboratory tests at the end of the treatment relative to the baseline values. After completing the treatment, investigators and patients assessed the acceptability of the study medication using a four-point scale (very good, good, moderate, poor).
Statistical methods
An adaptive design with one interim analysis [10, 11] , combined with a multiple-testing procedure for a closed family of hypotheses [12, 13] , controlling the multiple alevel of 5%, was carried out. The interim analysis was intended to lead to either early termination in case of suf®cient or missing effects or continuation with a second independent trial step using the adaptively calculated sample size. Three hierarchical one-sided null hypotheses were stipulated as follows: (1) the overall treatment effect (O'Brien's rank statistics [14] involving the changes from baseline for the two primary variables), and the changes from baseline in (2a) bladder capacity and (2b) volume at ®rst unstable contraction. An adaptive procedure using Mann±Whitney tests was conducted as follows. If the P value from the overall test in the interim analysis was: (a) P 1 f0.0263, the superiority of TCl over placebo was accepted, and the study was stopped prematurely. The elementary null hypotheses (2a and 2b) were then tested simultaneously at the same signi®cance level (closed-test procedure); (b) P 1 o0.4, the superiority of TCl over placebo could not be shown, and the study was to be stopped; (c) 0.0263fP 1 f0.4, a second step followed. The sample size was calculated adaptively and the ®nal analysis was performed at the signi®cance level of 0.0087/P 1 .
The choice of one-sided statistical tests is an assumption of Bauer and Ko Èhne's procedure [10] , and justi®ed because the aim of the study was to con®rm the superiority of TCl over placebo, as shown previously in another independent clinical trial using two-sided testing [15] . The treatment effect was estimated using the Hodges±Lehmann estimator [16] and the 95% CI. The secondary variables were analysed descriptively. Ef®cacy was analysed for the intent-to-treat (ITT) and the perprotocol (PP) populations.
Sample size
The sample size of 100 patients per group was estimated from a ®xed-sample design (assuming a one-sided t±test, 3% increase in sample size from using nonparametric methods, a=0.05, power = 0.90, standardized treatment difference = 0.47, dropout rate = 20%). The interim analysis was planned after treating about twothirds of the patient population.
The ITT and safety analysis included all patients who received randomized study medication. The PP analysis comprised all patients who had completed the study with no major protocol violations and for whom second values from the urodynamic measurements were available. Possible reasons for premature termination of the study or withdrawal from treatment were insuf®cient compliance, adverse events, decision by either the patient or the investigator, UTIs, insuf®cient data on urodynamic measurements, or other reasons.
Results
The interim analysis was performed for the ITT population (n=133) and the PP population (n=82). The results for the ITT population are given unless otherwise stated. The test for the overall hypothesis yielded a one-sided P 1 of 0.0067 (f0.0263). Therefore, the overall superiority of TCl over placebo was con®rmed and the study was stopped. Furthermore, the treatment differences for the maximum cystometric bladder capacity (one-sided P=0.0089) and volume at ®rst unstable contraction (one-sided P=0.0124) were statistically signi®cant, with values of <0.0263 in either case. Consequently, TCl was shown to be superior to placebo for the primary variables.
The ®nal analysis comprised all patients entering the study (ITT n=208; PP n=132) and thus also included the patients recruited while the interim analysis was performed (overrunning) [17] . The results from the interim and ®nal analyses were comparable, and there were no marked differences between the PP and the ITT populations.
The demographic data and baseline values of the ef®cacy variables were well balanced between the treatment groups (. Table 1 ). A summary of the changes in the ef®cacy variables from baseline to the end of the study is presented in . Table 2 . The maximum cystometric bladder capacity increased markedly in the TCl group, whereas there was a slight decrease in the placebo group. The median treatment difference between the TCl and placebo groups (ITT, 22.0 mL) was statistically signi®-cant (one-sided P=0.0054). There was a similar treatment effect (28.0 mL) in the PP population (onesided P=0.0232). The volume at ®rst unstable contraction increased markedly during TCl treatment. The median treatment differences were 45.0 mL (ITT, onesided P=0.0015) and 62.0 mL (PP, one-sided P=0.0038). In the TCl group, all secondary ef®cacy variables improved (Table 2) ; again, the improvements for most were more pronounced in the PP population (data not shown).
In the overall assessment of ef®cacy, the investigators recorded more patients with a marked (26) or slight (30) improvement in the TCl group than in the placebo group (17 and 26, respectively). Comparable results were obtained from the patient's assessment of ef®cacy.
Many of the patients had abnormal bladder function on urodynamic testing at baseline, with high values of bladder capacity (median 350 mL). In a subgroup analysis in patients with a bladder capacity of o350 mL, maximum cystometric bladder capacity showed a greater improvement in the TCl group than the placebo group (median treatment effect 58.0 mL, one-sided P<0.001). Similarly, this population had greater improvements in the volume at ®rst unstable contraction in the TCl than in the placebo group (median treatment effect 90.0 mL, onesided P<0.001).
Safety
In the TCl group, 71 (68%) patients experienced adverse events, compared with 64 (62%) patients in the placebo group. More than one adverse event may have occurred in an individual patient, and a speci®c event was occasionally documented several times. The total numbers of adverse events reported in the TCl and placebo group were 191 and 167, respectively (safety population, n=208). The most frequently reported adverse event was dry mouth (TCl, 43; placebo, 18), followed in frequency by gastrointestinal disorders, e.g. abdominal pain, dyspepsia, and nausea. Remarkably, there were more reports of dizziness and headache in the placebo group ( 15 and 36, respectively) than in the TCl group (11 and 25) .
Five patients (four TCl, one placebo) experienced a serious adverse event (SAE) during the study. Only one SAE in the TCl group was classi®ed as probably related to the study medication. The patient experienced headache, thirst and urinary retention. All other SAEs were considered unrelated to the study medication and all patients recovered completely.
All adverse events were transient and reversible, and most events were classi®ed as not serious. The frequency of adverse events in the present study was slightly greater than that normally expected, possibly because of the method of eliciting adverse events from the patients' diary cards. There were no clinically relevant changes in the laboratory variables (haematology, blood chemistry and urine analysis); similarly, vital signs, physical examinations, and ECGs caused no safety concerns.
Most patients in either group rated the acceptability of study medication as good or very good (TCl, 50% and 37%, respectively; placebo, 40% and 29%).
Discussion
The treatment of detrusor instability with anticholinergic agents aims to inhibit involuntary detrusor contractions, increase bladder capacity and decrease the frequency of micturition. The ef®cacy and safety of the anticholinergic TCl has previously been shown in clinical trials in patients with detrusor hyper-re¯exia caused by suprasacral spinal cord injuries [6±8] and in patients with urge incontinence [15, 18] .
The present double-blind, randomized, placebo-controlled study in patients with idiopathic detrusor instability showed similar results. TCl had a statistically and clinically signi®cant effect on bladder capacity and the volume at ®rst unstable contraction. This clear superiority of TCl over placebo justi®ed the early termination of the study, in compliance with the discontinuation rules de®ned in the protocol. The results are also in good agreement with those obtained in two double-blind, randomized trials comparing TCl 20 mg twice daily with oxybutynin 5 mg three times daily, which is considered the standard treatment in detrusor instability. The two regimens were of equal value as assessed by objective urodynamic variables, but TCl was preferable for patient acceptability [6, 7] .
In summary, the results of this clinical trial in 208 patients with detrusor instability showed a clear improvement in maximum bladder capacity and volume at ®rst unstable contraction with TCl. These ®ndings are in line with those reported in other recently completed studies [15, 18] and con®rm that TCl is effective in the treatment of detrusor instability. The 8% placebo response [19] noted in the present trial is much lower than that observed in other similar trials where placebo responses of 40% [20] and 42% [21] were reported.
Tapp et al. [21] concluded that the success of anticholinergic treatment for detrusor instability relies on the balancing of bene®ts and side-effects, particularly because the perception and acceptance of side-effects and response to anticholinergic agents are highly variable among individual patients.
In this clinical study, the good treatment effects of TCl were accompanied by a favourable safety pro®le. The adverse events were those anticipated for an anticholinergic agent, with dry mouth reported most frequently. There were only a few reports of constipation and urinary retention, and the investigators considered that most of these were unrelated to the study medication.
There were remarkably many reports of CNS disorders, e.g. dizziness and headache, in the placebo group. This might be provoked because the overall incidence of adverse events was the subject of daily active enquiries, leading to arti®cially increased frequencies.
In conclusion, TCl improved bladder function in adults with detrusor instability. The safety assessment revealed the adverse events commonly associated with anticholinergic agents. The resulting favourable bene®t to risk ratio con®rms the therapeutic value of TCl in the clinical management of detrusor instability.
